

CES HK Biotechnology Index Methodology



Contents

Pre	face	2 -
1.	Index Name and Code	3 -
2.	Base Date and Base Index	3 -
3.	Index Eligibility	3 -
	Index Calculation	
5.	Periodic Review of Constituents	5 -
6.	Amendments and Supplements to Index Methodology	5 -
	Information Disclosure	
	ntact Us	



Preface

China Exchanges Services Company Ltd. (CESC) has appointed China Securities Index Co., Ltd. (CSIC) for index calculation, maintenance and dissemination. The index methodology is developed by mutual agreement between CESC and CSIC.

CES HK Biotechnology Index (CES HK Biotech) is a price return index provides a measure of market performance for biotechnology companies listed on the Stock Exchange of Hong Kong Limited (SEHK).

Index Name	Launch Date	Constituents
CES HK Biotech	14-11-2018	Consists of biotechnology companies listed on the SEHK.



1. Index Name and Code

Index Name	Abbreviation	Index Currency	Index Code
CES HK Biotechnology Index	CES HK Biotech	HKD	CESHKB
CES HK Biotechnology Index	CES HK Biotech	CNY	CES010
CES HK Biotechnology Total Return Index	CES HK Biotech TR	HKD	CES210
CES HK Biotechnology Total Return Index	CES HK Biotech TR	CNY	CES110

2. Base Date and Base Index

The base date is Dec 12, 2014. The base point is 2000.

3. Index Eligibility

3.1 Index Universe

The index universe for CES HK Biotech is comprised of common stocks with primary or secondary listing on the Main Board of SEHK.

3.2 Selection Criteria

The constituents are selected as follows:

- Biotech Sector Screen. Eligible stocks must be classified as either "Biotechnology Company" according to the Industry Classification, or "Biotechnology Company" listing under Chapter 18A of the Stock Exchange of Hong Kong Main Board Listing Rules;
- □ **Listing History Screen.** Exclude stocks with a listing history of less than three months;
- □ **Liquidity Screen**. Exclude stocks with a daily average turnover



velocity[^] (i.e. daily shares traded divided by total listed shares) of less than 0.05%, and meanwhile with a daily average trading value of less than HK\$5 million in the most recent year;

- □ **Size Screen.** Exclude stocks with a daily average total market capitalisation of less than HK\$1.5 billion.
- □ Following above screens, the top 30 stocks ranked by daily average total market capitalisation^ in the most recent year are chosen for inclusion in the index. If the number of remaining eligible stocks is less than 30, all eligible stocks will be included.

^For newly listed stocks, the daily average turnover velocity, daily average trading value or daily average total market capitalisation is derived from the data between the fourth trading day and the Review Cutoff Date.

4. Index Calculation

The CES HK Biotech is calculated according to the formula below:

Adjusted market capitalisation = \sum (Price × Adjusted No. of shares × Foreign Exchange Rate × Weight Factor).

For the calculation of the adjusted no. of shares, please refer to CES Index Calculation and Maintenance Methodology for further details. If any constituent stock is multi-listed, the calculation of its weight factor will base on the investable shares, which are currently listed and traded on the SEHK.

The Weight Factor is set between 0 and 1, so that no constituent accounts for more than 10% of the index. However, if the number of constituents is less than



20, a 15% cap will be applied to the index. If the number of constituents is less than 8, a 25% cap will be applied to the index. If the number of constituents is less than 5, the Index will be equally weighted.

5. Periodic Review of Constituents

5.1 Periodic Review

The CES HK Biotech is adjusted and rebalanced semi-annually. The index reconstitution and float share adjustments are implemented on the next trading day after the second Friday of each June and December.

Weight Factor is assigned to each constituent at each semiannually rebalancing.

The effective date is the same as that of the constituent adjustment. The Weight

Factor stays the same until the next rebalancing.

5.2 Ongoing Adjustment

When special events occur affecting the representativeness and investability of the index, requisite non-regular adjustments will be made to the index constituents of CES HK Biotech. When deletion happens, deleted stocks will not be replaced until next regular review of index constituents.

6. Amendments and Supplements to Index Methodology

In response to market development and clients' feedback, CESC and CSIC will amend or supplement the Index Methodology from time to time as appropriate. Proposed changes will be announced to the market prior to implementation.



7. Information Disclosure

To maintain the objectiveness, independence and authority of the index, CESC has adopted a stringent information disclosure policy to ensure transparency, openness and fairness.

- Any personnel of CESC and CSIC are forbidden to divulge any information to any third party, including private media interviews before such information is disclosed to the public.
- Media used for information disclosure includes but not limited to website of CESC and CSIC.
- In general, result of the regular index review is published two weeks before the effective date. Non-regular adjustment in constituents will be published as soon as practicable. Changes in index methodology and index maintenance rules are usually published two weeks before the effective date.



Contact Us

For further details, please contact:

Index licensing Enquiries

China Exchanges Services Company Limited

Suites 906-908, 9/F, Two Exchange Square

8 Connaught Place, Central, Hong Kong

Tel: 852 2803 8200

Fax: 852 2868 3770

Email: cescinfo@cesc.com

Website: http://www.cesc.com/

Customer Service

China Securities Index Co., Ltd.

13F, Bldg 6, Lujiazui Financial Century Plaza, No.308 Jinkang Road

Pudong, Shanghai, PRC, 200127

Tel:0086 21 5018 5500

Fax:0086 21 5018 6368

Email: csindex@sse.com.cn

Website: http://www.csindex.com.cn/